EUCRISA (crisaborole ointment, 2 %) is indicated for topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 3 months of age and older.
Pediatrics (3 months to <18 years): Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of EUCRISA have been established in pediatric patients age 3 months and older for topical treatment of mild to moderate atopic dermatitis.
Pediatrics (3 months of age): No data are available to Health Canada, therefore, Health Canada has not authorized an indication for pediatric patients below the age of 3 months.
Geriatrics (≥ 65 years of age):
Evidence from clinical studies of EUCRISA did not include sufficient numbers of patients 65 years of age and over to determine whether they respond differently from younger patients.